Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 201–300 of 889
Muscarinic Agonist Therapy of Alzheimer's Disease
Bruno, G. (1986) · Archives of Neurology · doi:10.1001/archneur.1986.00520070017009 · Cited by 85
The distribution of somatostatin‐like immunoreactivity in the monkey hippocampal formation
Bakst, I., Morrison, J. H., & Amaral, D. G. (1985) · Journal of Comparative Neurology · doi:10.1002/cne.902360402 · Cited by 86
Fine, A., Dunnett, S. B., Björklund, A., Clarke, D. J., & Iversen, S. D. (1985) · Neuroscience · doi:10.1016/0306-4522(85)90093-4 · Cited by 84
Ca2+ Permeable AMPA Channels in Diseases of the Nervous System
Weiss, J. H. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00042 · Cited by 82
“, 1982), and there is evidence for loss of other subpopulations of interneurons including those containing parvalbumin or somatostatin (Davies et al., 1980; Rossor et al., 1980; Arai et al., 1987).”
BackgroundRestoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats
Haroutunian, V. H., Kanof, P. D., Tsuboyama, G. K., & Davis, K. L. (1990) · Brain Research · doi:10.1016/0006-8993(90)90280-o · Cited by 83
Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptidesi
Fleisher-Berkovich, S., Filipovich-Rimon, T., Ben-Shmuel, S., Hülsmann, C., Kummer, M. P., & Heneka, M. T. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-61 · Cited by 80
“In AD, elimination of SST from the cortex and hippocampus is correlated to reduced cognitive function and memory impairment [10,17].”
BackgroundArai, H., Moroji, T., & Kosaka, K. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90353-7 · Cited by 82
Neuropeptides, mental performance and aging
de Wied, D., & van Ree, J. M. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90696-8 · Cited by 84
GABA—Peptide Neurons of the Primate Cerebral Cortex: A Limited Cell Class
Jones, E. G., Hendry, S. H. C., & DeFelipe, J. (1987) · Cerebral cortex · doi:10.1007/978-1-4615-6616-8_6 · Cited by 85
The Olfactory System and Alzheimer's Disease
Moyano, H. F., & Barragán, E. I. (1989) · International Journal of Neuroscience · doi:10.3109/00207458909084824 · Cited by 88
Tilson, H. A., McLamb, R. L., Shaw, S., Rogers, B. C., Pediaditakis, P., & Cook, L. L. (1988) · Brain Research · doi:10.1016/0006-8993(88)91326-1 · Cited by 84
Shetty, A. K., & Bates, A. A. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.019 · Cited by 86
“Decreased inhibitory neurotransmission likely also occurs in AD as brain concentrations of GABA and SST are reduced in the brain and the cerebrospinal fluid (Davies et al., 1980; Hardy et al., 1987; Seidl et al., 2001).”
BackgroundMartignoni, E., Petraglia, F., Costa, A., Bono, G., Genazzani, A. R., & Nappi, G. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1990.tb00994.x · Cited by 80
Wood, P. L., Etienne, P. E., Lal, S., Nair, N. P. V., Finlayson, M. H., Gauthier, S. G., Palo, J., Haltia, M., Paetau, A. E., & Bird, E. D. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90200-9 · Cited by 81
Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease
Saiz-Sanchez, D., De la Rosa-Prieto, C., Ubeda-Banon, I., & Martinez-Marcos, A. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0771-3 · Cited by 79
Sanchez‐Mejias, E., Nuñez‐Diaz, C., Sanchez‐Varo, R., Gomez‐Arboledas, A., Garcia‐Leon, J. A., Fernandez‐Valenzuela, J. J., Mejias‐Ortega, M., Trujillo‐Estrada, L., Baglietto‐Vargas, D., Moreno‐Gonzalez, I., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12785 · Cited by 77
Gavilán, M. P., Revilla, E., Pintado, C., Castaño, A., Vizuete, M. L., Moreno‐González, I., Baglietto‐Vargas, D., Sánchez‐Varo, R., Vitorica, J., Gutiérrez, A., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04787.x · Cited by 77
“1997), AD cases (Davies et al. 1980; van de Nes et al., 2002) and AD models (Ramos et al.”
ResultNeural Correlates of Cognitive Impairment in Alzheimer's Disease
Van Hoesen, G. W., & Damasio, A. R. (1987) · Comprehensive Physiology · doi:10.1002/cphy.cp010522 · Cited by 80
The role of clinical neuropsychology in the neurological diagnosis of Alzheimer's disease
Spinnler, H. R., & Sala, S. D. (1988) · Journal of Neurology · doi:10.1007/bf00314172 · Cited by 87
Gaspar, P., Berger, B., Lesur, A., Borsotti, J. P., & Febvret, A. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90197-7 · Cited by 83
General Aspects of the Biology and Function of Somatostatin
Patel, Y. (1992) · Basic and clinical aspects of neuroscience · doi:10.1007/978-3-642-76948-1_1 · Cited by 100
Striatal dopamine receptors in Alzheimer-type dementia
Cross, A. J., Crow, T. J., Ferrier, I. N., Johnson, J. A., & Markakis, D. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90341-0 · Cited by 78
Nakamura, S., & Vincent, S. R. (1986) · Brain Research · doi:10.1016/0006-8993(86)91099-1 · Cited by 80
Subset of neurons characterized by the presence of NADPH‐diaphorase in human substantia innominata
Ellison, D. W., Kowall, N. W., & Martin, J. B. (1987) · The Journal of Comparative Neurology · doi:10.1002/cne.902600207 · Cited by 83
Taurine improves learning and retention in aged mice
Idrissi, A. E. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.070 · Cited by 77
“Furthermore , one of the most consistent neurochemical abnormality in Alzheimer's disease is a reduction in cortical somatostatin [8] [27].”
Alzheimer's Disease and Other Dementing Disorders
Raskind, M. A., & Peskind, E. R. (1992) · Elsevier eBooks · doi:10.1016/b978-0-12-101277-9.50022-x · Cited by 78
Rossor, M. N., Rehfeld, J. F., Emson, P. C., Mountjoy, C. Q., Roth, M., & Iversen, L. L. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90334-9 · Cited by 77
Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., & Nappi, G. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260903 · Cited by 76
“Nevertheless, it should also be noted that a degeneration of NPY-ergic cells has been observed in the temporal cortex and hippocampus of DAT patients and that somatostatin, coexisting with NPY in many cortical areas (Chronwall et al., 1984; Hendry etal., 1984), is clearly reduced in this pathology, either in brain tis…”
BackgroundAcute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease
Thal, L. J., Masur, D. M., Sharpless, N. S., Fuld, P. A., & Davies, P. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90032-1 · Cited by 76
“While brain levels of other neurotransmitters, such as norepinephrine (Bondareff et al 1981) somatostatin (Davies et al 1980) and substance P (Crystal and Davies 1982) are also de-”
BackgroundSelf-citationUltrastructural localization of somatostatin‐like immunoreactivity in the rat dentate gyrus
Milner, T. A., & Bacon, C. E. (1989) · Journal of Comparative Neurology · doi:10.1002/cne.902900409 · Cited by 75
Dawbarn, D., Rossor, M. N., Mountjoy, C. Q., Roth, M., & Emson, P. C. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90455-6 · Cited by 79
Norris, P. J., Faull, R. L. M., & Emson, P. C. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00064-2 · Cited by 79
Laminar distribution of neuron degeneration in posterior cingulate cortex in Alzheimer's disease
Vogt, B. A., Hoesen, G. W. V., & Vogt, L. J. (1990) · Acta Neuropathologica · doi:10.1007/bf00307624 · Cited by 75
“Immunochemical and receptor binding studies have also implicated alterations in small populations of interneurons including somatostatinergic [3, 12 , 15, 32, 36, 38, 39] and neuropeptide Y-containing [9] neurons.”
BackgroundOrganization of Neuropeptide Y Neurons in the Mammalian Central Nervous System
Hendry, S. H. C. (1993) · The Biology of Neuropeptide Y and Related Peptides · doi:10.1007/978-1-59259-465-8_3 · Cited by 71
Regional changes in [3H]d-aspartate and [3H]TCP binding sites in Alzheimer's disease brains
Simpson, M. D. C., Royston, M. C., Deakin, J. F. W., Cross, A. J., Mann, D. M. A., & Slater, P. (1988) · Brain Research · doi:10.1016/0006-8993(88)90587-2 · Cited by 79
Delfs, J. R., Zhu, C.-H., & Dichter, M. A. (1984) · Science · doi:10.1126/science.6140757 · Cited by 74
Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.
Quirion, R. (1993) · PubMed · Cited by 73
Higuchi, M., Iwata, N., & Saido, T. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.02.013 · Cited by 89
Bloom, S. R., & Polak, J. M. (1987) · BMJ · doi:10.1136/bmj.295.6593.288 · Cited by 73
Neuropeptide Abnormalities in Patients With Early Alzheimer Disease
Davis, K. L., Mohs, R. C., Marin, D. B., Purohit, D. P., Perl, D. P., Lantz, M., Austin, G., & Haroutunian, V. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.11.981 · Cited by 72
“The somatostatin antisera are directed toward residues 6 to 10 of the somatostatin (1-14) molecule and recognize somatostatin (1-14) and somatostatin (1-28) on an equimolar basis.”
BackgroundMethodFerrer, I., Soriano, E., Tuñón, T., Fonseca, M., & Guionnet, N. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90250-b · Cited by 77
CSF somatostatin in Alzheimer's disease
Serby, M., Richardson, S. B., Twente, S., Siekierski, J., Corwin, J., & Rotrosen, J. (1984) · Neurobiology of Aging · doi:10.1016/0197-4580(84)90061-7 · Cited by 71
Cholinergic receptors in aging and Alzheimer's disease
Whitehouse, P. J., & Au, K. S. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90035-7 · Cited by 72
Cellular pathology in Alzheimer's and Parkinson's diseases
Price, D. L., Whitehouse, P. J., & Struble, R. G. (1986) · Trends in Neurosciences · doi:10.1016/0166-2236(86)90011-1 · Cited by 77
Somatostatin inhibition of adenylate cyclase activity in different brain areas
Schettini, G., Florio, T., Meucci, O., Landolfi, E., GRIMALDI, M., Ventra, C., & Marino, A. (1989) · Brain Research · doi:10.1016/0006-8993(89)90889-5 · Cited by 73
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
“Thus, GABAergic, cholinergic and glutamatergic neurotransmission systems are severely impaired [94–96] while loss of noradrenergic [61] and serotonergic neurons, as well as neurons producing somatostatin [97], corticotrophin-releasing factor, substance P and neuropeptide Y has also been described [98] (reviewed in [99…”
BackgroundFunctional Pharmacology in Human Brain
Raiteri, M. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.5 · Cited by 72
“Reduction of somatostatin levels in the cortical areas is an autoptic finding typical of Alzheimer’s disease (Davies et al., 1980; Beal et al., 1986; Dawbarn et al., 1986; Chan-Palay, 1987; Gabriel et al., 1993).”
BackgroundPomara, N., Singh, R., Deptula, D., LeWitt, P. A., Bissette, G., Stanley, M., & Nemeroff, C. B. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90071-1 · Cited by 68
Piercey, M. F., Vogelsang, G. D., Franklin, S. R., & Tang, A. H. (1987) · Brain Research · doi:10.1016/0006-8993(87)91186-3 · Cited by 67
Atack, J. R., Beal, M. F., May, C., Kaye, J. A., Mazurek, M. F., Kay, A. D., & Rapoport, S. I. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520270043019 · Cited by 72
Decreased muscarinic receptor binding in cerebral cortex and hippocampus in alzheimer's disease
Reinikainen, K. J., Riekkinen, P. J., Halonen, T., & Laakso, M. P. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90221-9 · Cited by 70
Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease.
Molloy, D. W., Guyatt, G. H., Wilson, D. B., Duke, R. J., Rees, L., & Singer, J. (1991) · PubMed · Cited by 76
Matsuoka, N., Kaneko, S., & Satoh, M. (1991) · Brain Research · doi:10.1016/0006-8993(91)90823-e · Cited by 68
Chronic Oral Physostigmine Without Lecithin Improves Memory in Alzheimer's Disease
Thal, L. J., Masur, D. M., Blau, A. D., Fuld, P. A., & Klauber, M. R. (1989) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1989.tb01567.x · Cited by 67
Hippocampal Somatostatin Interneurons, Long-Term Synaptic Plasticity and Memory
Honoré, È., Khlaifia, A., Bosson, A., & Lacaille, J. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.687558 · Cited by 75
“Blocking SST1R resulted in an increase in SOM concentration but had no effect on GABA concentration in vivo (De Bundel et al., 2010).”
BackgroundDysregulation of dynorphins in Alzheimer disease
Yakovleva, T., Marinova, Z., Kuzmin, A., Seidah, N. G., Haroutunian, V., Terenius, L. Y., & Bakalkin, G. Y. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.07.002 · Cited by 72
In vivo voltammetry with micro-biosensors for analysis of neurotransmitter release and metabolism
Crespi, F. (1990) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(90)90042-e · Cited by 66
Elevated CSF dynorphin A [1–8] in Tourette's syndrome
Leckman, J. F., Riddle, M. A., Berrettini, W. H., Anderson, G. M., Hardin, M., Chappell, P., Bissette, G., Nemeroff, C. B., Goodman, W. K., & Cohen, D. J. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90575-9 · Cited by 66
Buck, S. H., Deshmukh, P. P., Burks, T. F., & Yamamura, H. I. (1981) · Neurobiology of Aging · doi:10.1016/0197-4580(81)90033-6 · Cited by 69
Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex
Quigley, B. J., & Kowall, N. W. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90199-x · Cited by 67
Morrone, C. D., Raghuraman, R., Hussaini, S. A., & Yu, W. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00617-4 · Cited by 69
Unger, J. W., & Lange, W. (1992) · Acta Neuropathologica · doi:10.1007/bf00299414 · Cited by 68
Developmental expression of somatostatin in mouse brain. I. Immunocytochemical studies
Forloni, G., Höhmann, C. F., & Coyle, J. T. (1990) · Developmental Brain Research · doi:10.1016/0165-3806(90)90120-n · Cited by 65
Somatostatin in Alzheimer's disease and depression
Bissette, G., & Myers, B. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90534-v · Cited by 66
Davis, B. M., Mohs, R. C., Greenwald, B. S., Mathé, A. A., Johns, C. A., Horvath, T. B., & Davis, K. L. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb04184.x · Cited by 64
Somatostatin, tau, and β-amyloid within the anterior olfactory nucleus in Alzheimer disease
Saiz-Sanchez, D., Ubeda-Bañon, I., de la Rosa-Prieto, C., Argandoña-Palacios, L., Garcia-Muñozguren, S., Insausti, R., & Martinez-Marcos, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.06.010 · Cited by 63
“Somatostatin levels decline with normal aging (Lu et al., 2004) and cortical somatostatin immunoreactivity was also found to be systematically reduced in AD brain versus controls (Davies et al., 1980).”
BackgroundResultFitzgerald, L. W., & Dokla, C. P. J. (1989) · Brain Research · doi:10.1016/0006-8993(89)91450-9 · Cited by 70
Neurotransmitter systems in aging and senile dementia
McGeer, E. G. (1981) · Progress in Neuro-Psychopharmacology · doi:10.1016/0364-7722(81)90025-4 · Cited by 63
Moreau, J. P., & DeFeudis, F. V. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90107-x · Cited by 63
Brain somatostatin: Receptor-coupled transducing mechanisms and role in cognitive functions
Schettini, G. (1991) · Pharmacological Research · doi:10.1016/s1043-6618(05)80080-5 · Cited by 67
Matsuoka, N., Maeda, N., Yamaguchi, I., & Satoh, M. (1994) · Brain Research · doi:10.1016/0006-8993(94)90900-8 · Cited by 66
Neuropeptide Y-like immunoreactivity in neuritic plaques of Alzheimer's disease
Dawbarn, D., & Emson, P. C. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)90604-7 · Cited by 61
Cholinergic Drugs in Alzheimer's Disease
Davis, K. L., & Mohs, R. C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152008 · Cited by 61
Yang, Y., Zhu, X., Chen, Y., Wang, X., & Chen, R. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.067 · Cited by 60
Brain Somatostatin Receptors Are Up-Regulated In Somatostatin-Deficient Mice
Ramírez, J. L., Mouchantaf, R., Kumar, U., Otero-Corchón, V., Rubinstein, M., Low, M. J., & Patel, Y. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0068 · Cited by 60
Yates, C. M., Harmar, A. J., Rosie, R., Sheward, J., de Levy, G. S., Simpson, J. A., Maloney, A. F. J., Gordon, A., & Fink, G. (1983) · Brain Research · doi:10.1016/0006-8993(83)91224-6 · Cited by 60
Antemortem markers of Alzheimer's disease
Hollander, E., Mohs, R. C., & Davis, K. L. (1986) · Neurobiology of Aging · doi:10.1016/0197-4580(86)90164-8 · Cited by 60
Evidence that Somatostatin Enhances Endogenous Acetylcholine Release in the Rat Hippocampus
Araujo, D. M., Lapchak, P. A., Collier, B., & Quirion, R. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04937.x · Cited by 60
“This may be of therapeutic significance because several reports have demonstrated that deficits in SSlike immunoreactivity and SS receptors parallel those seen with cholinergic markers in Alzheimer’s disease (Davies et al., 1980; Beal et al., 1985; Hardy et al., 1985; Candy et al., 1985; Nakamura and Vincent, 1986).”
BackgroundMcKinney, M., Davies, P., & Coyle, J. T. (1982) · Brain Research · doi:10.1016/0006-8993(82)91133-7 · Cited by 60
Self-citationSomatostatin in Alzheimer's disease: A new Role for an Old Player
Solarski, M., Wang, H., Wille, H., & Schmitt-Ulms, G. (2018) · Prion · doi:10.1080/19336896.2017.1405207 · Cited by 62
“In fact, one of the earliest biochemical changes documented in the cerebral cortex of AD patients was an accelerated reduction in SST immunoreactivity [22].”
BackgroundGuennewig, B., Lim, J., Marshall, L., McCorkindale, A. N., Paasila, P. J., Patrick, E., Kril, J. J., Halliday, G. M., Cooper, A. A., & Sutherland, G. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-83872-z · Cited by 58
Homeostatic Disinhibition in the Aging Brain and Alzheimer's Disease
Gleichmann, M., Chow, V. W., & Mattson, M. P. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101674 · Cited by 58
“It also includes a marked increase in astrogliosis [11] and reactive microglia [12, 13], a loss of cholinergic projection neurons in the basal forebrain [14] a reduction in aminergic projections from midbrain regions [15, 16], a reduction in somatostatin levels [17] and most notably a loss of synapses and neurons [18].”
Etiology of sporadic Alzheimer’s disease: Somatostatin, neprilysin, and amyloid β peptide
Hama, E., & Saido, T. C. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.02.045 · Cited by 59
The amygdala in Alzheimer's disease: Neuropathology and Alz 50 Immunoreactivity
Unger, J. W., Lapham, L. W., McNeill, T. H., Eskin, T. A., & Hamill, R. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90063-p · Cited by 61
Choline acetyltransferase immunoreactivity in neuritic plaques of Alzheimer brain
Armstrong, D. M., Bruce, G., Hersh, L. B., & Terry, R. D. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90564-1 · Cited by 61
Self-citationWeiss, J. H., Yin, H. Z., & Choi, D. W. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90494-4 · Cited by 64
Brain Amyloid and Alzheimer Disease
Vinters, H. V., Miller, B. L., & Pardridge, W. M. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-1-41 · Cited by 58
Multiple receptor regulation of cyclic nucleotides in rat pinealocytes
Chik, C. L., & Ho, A. K. (1989) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(89)90002-3 · Cited by 58
Somatostatinergic neurites in senile plaques of aged non-human primates
Struble, R. G., Kitt, C. A., Walker, L. C., Cork, L. C., & Price, D. L. (1984) · Brain Research · doi:10.1016/0006-8993(84)90057-x · Cited by 58
Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease
Burke, W. J., Park, D. H., Chung, H. D., Marshall, G. L., Haring, J. H., & Joh, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90342-9 · Cited by 58
Distribution of somatostatin‐like immunoreactivity in the monkey amygdala
Amaral, D. G., Avendañto, C., & Benoit, R. (1989) · Journal of Comparative Neurology · doi:10.1002/cne.902840211 · Cited by 57
Gustilo, M. C., Markowska, A. L., Breckler, S. J., Fleischman, C. A., Price, D. L., & Koliatsos, V. E. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990322)405:4<491::aid-cne4>3.0.co;2-n · Cited by 57
Candy, J. M., Perry, E. K., Perry, R. H., COURT, J. A., Oakley, A. E., & Edwardson, J. A. (1986) · Progress in brain research · doi:10.1016/s0079-6123(08)64300-9 · Cited by 59
Polymorphic human somatostatin gene is located on chromosome 3.
Naylor, S. L., Sakaguchi, A. Y., Shen, L., Bell, G. I., Rutter, W. J., & Shows, T. B. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.9.2686 · Cited by 57
Piracetam combined with lecithin in the treatment of Alzheimer's disease
Growdon, J. H., Corkin, S., Huff, F. J., & Rosen, T. J. (1986) · Neurobiology of Aging · doi:10.1016/0197-4580(86)90007-2 · Cited by 59
CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression
Molchan, S. E., LAWLOR, B. A., Hill, J., Martínez, R. A., Davis, C. L., Mellow, A. M., Rubinow, D. R., & Sunderland, T. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90253-i · Cited by 56
“…(SLI) has been a consistent finding in _many studies of the cerebrospinal fluid (CSF) and brains of patients with Alzheimer's disease (AD) (Davies et al 1980; Francis et al 1984; Sunderland et al 1987; Davis et al 1988), as well as in the CSF of patients with major depression (Rubinow et…”
BackgroundNag, S., Yee, B. K., & Tang, F. M. K. (1999) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00196-3 · Cited by 60
Arai, H., Moroji, T., Kosaka, K., & Iizuka, R. (1986) · Brain Research · doi:10.1016/0006-8993(86)90873-5 · Cited by 56
Hörtnagl, H., Potter, P. E., & Hanin, I. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90210-7 · Cited by 59
Bergström, L., Garlind, A., Nilsson, L. N. G., Alafuzoff, I. I., Fowler, C. J., Winblad, B. G., & Cowburn, R. F. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90149-2 · Cited by 57
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.